Phase 3 Readout~month

Phase 3 Topline: A Phase II/III, Randomised, Double-Blind Clinical Trial to Determine the Safety and Efficacy of IHL-

Name: Phase 3 Topline: A Phase II/III, Randomised, Double-Blind Clinical Trial to Determine the Safety and Efficacy of IHL-
Start: 2026-12-01

December 1, 2026

Company: Incannex Healthcare Inc. (IXHL)
Drug: obstructive
Indication: Obstructive Sleep Apnea

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start Free Full Calendar

Phase 3 Topline: A Phase II/III, Randomised, Double-Blind Clinical Trial to Determine the Safety and Efficacy of IHL- — IXHL Phase 3 Readout | BioSniper